Hear from L. Elizabeth Budde, M.D., Ph.D., of @CityofHope, who presents data on mosunetuzumab plus polatuzumab vedotin in pts w/ R/R large B-cell #lymphoma. #oncology onclive.com/view/mosunetuz…

Dr. Vito Imbasciani from California Institute for Regenerative Medicine is delivering great speech on the history and mission of CIRM. I am thankful that CIRM continues to show strong commitment to our research, training and expanding the availability of innovative treatments, “tomorrow’s treatment” to all.

What an awesome symposium: Fantastic combo of science, data, and clinical care. Super impressed by the moderators’ ability to engage the audience. Love the idea of having the speaker pick a walk up song.

With Reem Karmali Тyler 21st International Ultmann Chicago Lymphoma Symposium. Had a great time! BioAscend

Can’t stress enough about the importance of a great partnership. Such a privilege to work with cell therapists and colleagues City of Hope Department of Medical Oncology City of Hope

🙌 It was great to participate in the educational case-based video series w/ outstanding experts Wilmot Cancer Institute Carla Casulo, MD & City of Hope L. Elizabeth Budde, M.D., Ph.D. for the ASCO The ASCO Post on treatment options for relapsed/refractory follicular #lymphoma (SEE: ascopost.com/video-roundtab…).

Did u know the AACR Journals has simultaneous publication opportunities? Here's a picture of first author Sumanta K. Pal (Sumanta K. Pal, MD, FASCO) presenting his article that published at #AACR24. aacrjournals.org/cancerdiscover…

I know one of them and very proud!

So well deserved! Edward S. Kim, MD, MBA, FACP, FASCO Writing a new chapter and extending hope to many COH patients.

More CAR T options for MCL patients. Congrats to Michael Wang, MD and team.

ASCO2024 Bispecific antibody education session is live now. Please join Monique Minnema, Dr. Paolo Strati, and me for a great discussion.

So glad to see Lawrence is doing so well. Congrats to Lawrence Liu Murali Janakiram

A beautiful showcase of bench to bedside translation of COH’s homegrown CAR T. All happened on our campus. Big congrats to Saul “Cancer Asskicker” Priceman Tanya Dorff, medonc GU team, Immunotherapy Modality team/COH IEC program.

Very excited to join Prof. S. Dietrich, and prof. Ladetto for a symposium at EHA later today. Saturday 15 June 2024, 18.00–18.45 Venue: GOYA HAll 2 Title: The evolving role of T-cell engaging bispecific antibodies in relapsed/refractory follicular lymphoma

Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell NHL: longest follow-up using bispecific antibodies in NHL; time limited treatment. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…

Phenomenal work from #JohnBairdMD, a rising star in our IEC program.

Wow, Dino in action. Love it.

Listen in as expert oncologists expand on contemporary sequencing with CD20xCD3 bispecific antibodies in R/R diffuse-large B-cell #lymphoma. Matt Lunning D.O. L. Elizabeth Budde, M.D., Ph.D. Leo Gordon Frederick L. Locke #oncology #hematology onclive.com/view/contempor…

Three patients of mine treated with Mosun at 1.6mg q3weeks back in 2016, have remained in remission. Mosun was approved in 12.2022. The GO29781 clinical trial gave them access to “tomorrow’s medicine” 6 years earlier.

Endorse. Endorse. Endorse.